US00877 1966B2 (12) UnitedO States Patent (10) Patent No.: US 8,771,966 B2 Dennis et al. (45) Date of Patent: Jul. 8, 2014 (54) IMMUNO-PET IMAGING OF ANTIBODIES RE30,985 E 6/1982 Cartaya AND IMMUNOCONUGATES AND USES 3. E. A 3. 3: RCai Ca.al THEREFOR 4,364,866 A 12/1982 Asai et al. 4,371.533. A 2, 1983 Akimoto et al. (71) Applicant: Genentech, Inc., South San Francisco, 4.419,446 A 12/1983 Howley et al. CA (US) 4.424,219 A 1/1984 Hashimoto et al. 4.450,254 A 5/1984 Isley et al. (72) Inventors: Mark Dennis, San Carlos, CA (US); Jan 3.288 A 12.8 s Marik, Hillsborough, CA (US); Paul 4657.866 A 4, 1987 RW, Polakis, Mill Valley, CA (US); Bonnee 4,676.980 A 6, 1987 Segal et al. Rubinfeld, Danville, CA (US); Simon 4,767,704 A 8/1988 Cleveland et al. Williams, Redwood City, CA (US) 4,816,567 A 3/1989 Cabilly et al. 4,927,762 A 5, 1990 Darfler (73) Assignee: Genentech, Inc., South San Francisco, 4,965,1994,933,294 A 10/19906, 1990 CaponWaterfield et al. et al. CA (US) 4,970,198 A 1 1/1990 Lee et al. 4,975,278 A 12/1990 Senter et al. (*) Notice: Subject to any disclaimer, the term of this 5,053,394 A 10/1991 Ellestad et al. patent is extended or adjusted under 35 Sis A 3. 3: Fi trometal U.S.C. 154(b) by 0 days. 5,122,469 A 6/1992 MatherISO et al. 5,208,020 A 5/1993 Chari et al. (21) Appl. No.: 13/692,888 5,264.365 A 1 1/1993 Georgiou et al. 5,316,757 A 5/1994 Sherry et al. (22) Filed: Dec. 3, 2012 5,342,606 A 8/1994 Sherry et al. 5,362,852 A 11/1994 Geoghegan (65) Prior Publication Data 5,385,893 A 1, 1995 Kiefer 5,401,638 A 3, 1995 Carney et al. US 2013/O157289 A1 Jun. 20, 2013 5,416,064 A 5/1995 Chari et al. 5,428,139 A 6/1995 Kiefer et al. 5,428, 155 A 6/1995 Sherry et al. Related U.S. Application Data 5,462,725 A 10, 1995 Kiefer et al. (63) Continuation of application No. (Continued) PCT/US2011/038923, filed on Jun. 2, 2011. FOREIGN PATENT DOCUMENTS (60) Provisional application No. 61/351,195, filed on Jun. 3, 2010 EP OOO3O89 B1 8, 1981 s EP O404 097 6, 1990 (51) Int. Cl. (Continued) GOIN33/53 (2006.01) (52) U.S. Cl. OTHER PUBLICATIONS USPC ............................................. 435/7.1; 435/7.2 (58) Field of Classification Search Aerts et al., “Disparity between in vivo EGFR expression and Zr None labeled cetuximab uptake assessed with PET'J Nucl Med. 50: 123 See application file for complete search history. 131 (2009). Albert et al., “Direct synthesis of DOTA-DPhe-octreotide and (56) References Cited (DOTA-DPhe'.Tyr-octreotide (SMT487): Two conjugates for sys temic delivery of radiotherapeutical nuclides to Somatostatin recep U.S. PATENT DOCUMENTS tor positive tumors in man” Bioorg Med Chem Lett 8:1207-1210 ( 1998). 3,720,760 A 3, 1973 Bennich et al. 3,773.919 A 11, 1973 Boswell et al. (Continued) 3,896,111 A 7/1975 Kupchan et al. 4,137,230 A 1/1979 Hashimoto et al. 4.248,8704,151,042 A 4/19792/1981 HigashideMiyashita etet al. Primary Examinerin a Jacob Cheu 4,256,746 A 3/1981 Miyashita et al. (74) Attorney, Agent, or Firm — Jessica L. Richardson 4,260,608 A 4, 1981 Miyashita et al. 4,265,814 A 5, 1981 Hashimoto et al. 4,275,149 A 6, 1981 Litman et al. (57) ABSTRACT 4.294,757 A 10, 1981 Asai 388 3. A 33. Siski, etal Anti-STEAP-1 antibodies and immunoconjugates thereofare 43.08.269 A 12/1981 Miyashita et al. provided. Methods of using anti-STEAP-1 antibodies and 4,309.428 A 1/1982 Miyashita et al. immunoconjugates thereof are provided. Methods of detect 1.33- K - A 3.18: EMSea ea.1 ing or determining the presence of STEAP-1 proteins are 4,317,821 A 3/1982 Miyashita et al. provided. 4,318,980 A 3/1982 Boguslaski et al. 4.322,348 A 3, 1982 Asai et al. 4.331,598 A 5/1982 Hasegawa et al. 9 Claims, 51 Drawing Sheets US 8,771,966 B2 Page 2 (56) References Cited FOREIGN PATENT DOCUMENTS U.S. PATENT DOCUMENTS EP O 425 235 B1 9, 1996 EP 1391213 A1 2, 2004 5,480,990 A 1/1996 Kiefer et al. WO 87/OO.195 A1 1, 1987 5,500,362 A 3, 1996 Robinson et al. WO 90,03430 A1 4f1990 5,508,192 A 4, 1996 Georgiou et al. WO 91/00360 A1 1, 1991 5,545,806 A 8/1996 Lonberg et al. WO 91705264 A1 4f1991 5,545,807 A 8, 1996 Surani et al. WO 91 10741 A1 7, 1991 5,569,825 A 10/1996 Lonberg et al. WO 92fOO373 A1 1, 1992 5,571,894 A 11/1996 Wells et al. WO 92.09690 A2 6, 1992 5,585,089 A 12/1996 Queen et al. WO 93,01161 A1 1, 1993 5,587,458 A 12/1996 King et al. WO 93,06213 A1 4f1993 5,606,040 A 2f1997 McGahren et al. WO 93,08829 A1 5, 1993 5,624,821 A 4/1997 Winter et al. WO 93.16.185 A2 8, 1993 5,625,126 A 4/1997 Lonberg et al. WO 93.21232 A1 10, 1993 5,633,425 A 5/1997 Lonberg et al. WO 94/11026 A2 5, 1994 5,635,483. A 6, 1997 Pettit et al. WO 94.29351 A2 12, 1994 5,641,870 A 6, 1997 Rinderknecht et al. WO 94.29351 A3 12?1994 5,648,237 A 7, 1997 Carter WO 96.O7754 A1 3, 1996 5,648,260 A 7, 1997 Winter et al. WO 96.O7754 R3 3, 1996 5,661,016 A 8/1997 Lonberg et al. WO 96.33735 A1 10, 1996 5,663,149 A 9, 1997 Pettit et al. WO 96.34096 A1 10, 1996 5,693,762 A 12/1997 Queen et al. WO 98.24893 A2 6, 1998 5,712.374. A 1/1998 Kuntsmann et al. WO 98.58964 12/1998 5,714,586 A 2, 1998 Kunstmann et al. WO 99.22764 A1 5, 1999 5,731, 168 A 3, 1998 Carter et al. WO 99,51642 A1 10, 1999 5,739,116 A 4, 1998 Hamann et al. WO OO/42O72 T 2000 5,739,277 A 4, 1998 Presta et al. WO 006 1739 A1 10, 2000 5,739,294 A 4, 1998 Kiefer et al. WO 01.00245 A2 1, 2001 5,750,660 A 5, 1998 Kiefer et al. WO 01.00245 A3 1, 2001 5,767,237 A 6, 1998 Sakakibara et al. WO O1/29246 A1 4/2001 5,767.285 A 6, 1998 Hamann et al. WO Of 45746 A2 6, 2001 5,770,701 A 6, 1998 McGahren et al. WO Of 45746 A3 6, 2001 5,770,710 A 6, 1998 McGahren et al. WO 02/088172 A2 11/2002 5,773,001 A 6, 1998 Hamann et al. WO 02/088172 A3 11, 2002 5,780,588 A 7, 1998 Pettit et al. WO O2/O88172 R1 11 2002 5,807,715 A 9, 1998 Morrison et al. WO O3,O11878 A2 2, 2003 5,821,337 A 10, 1998 Carter et al. WO O3,O11878 A3 2, 2003 5,834,456 A 11/1998 Kiefer et al. WO 03/043583 A2 5, 2003 5,834,597 A 11/1998 Tso et al. WO 03/043583 A3 5, 2003 5,840,523 A 11/1998 Simmons et al. WO 03/084570 A1 10, 2003 5,869,046 A 2f1999 Presta et al. WO O3,0851.19 A1 10, 2003 5,877,296 A 3, 1999 Hamann et al. WO 2004/OO 1993 A1 12/2003 6,027,888 A 2/2000 Georgiou et al. WO 2004/O10957 A2 2, 2004 6,083,715 A 7/2000 Georgiou et al. WO 2004/O10957 A3 2, 2004 6,124,431 A 9, 2000 Sakakibara et al. WO 2004/032828 A2 4/2004 6,165,745 A 12/2000 Ward et al. WO 2004/032828 A3 4/2004 6,194.551 B1 2/2001 Idusogie et al. WO 2004/043493 A1 5, 2004 6,329,503 B1 12/2001 Afar et al. WO 2004/056312 A2 T 2004 6,372,907 B1 4/2002 Lee et al. WO 2005/035586 A1 4/2005 6,441,163 B1 8, 2002 Chari et al. WO 2005/035778 A1 4/2005 6,528,624 B1 3/2003 Idusogie et al. WO 2005037992 A2 4/2005 6,602,677 B1 8, 2003 Wood et al. WO 2005/053742 A1 6, 2005 6,602,684 B1 8/2003 Umana et al. WO 2005/081711 A2 9, 2005 6,737,056 B1 5, 2004 Presta WO 2006/034488 A2 3, 2006 6,821,505 B2 11/2004 Ward WO 2006/034488 A3 3, 2006 6,824,780 B1 1 1/2004 Devaux et al. WO 2007/01 1968 A2 1, 2007 7,521,541 B2 4/2009 Eigenbrot et al. WO 2007/01 1968 A3 1, 2007 2002/0164328 A1 11/2002 Shinkawa et al.